EHA 2023 | Addressing the unmet needs of young patients with AML with adverse prognostic features
Andrius Žučenka
• 9 Jun 2023
Andrius Žučenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, comments on the challenges in the management of young and fit patients with acute myeloid leukemia (AML) with adverse prognostic features including complex karyotype, TP53 mutations, and other rare subtypes. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Abbvie: Consultancy, Honoraria, Other: Travel Expenses; Astellas: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Other: Travel Expenses; Pfizer: Consultancy
